Abiraterone combined with prednisone in the treatment of high-risk high-tumor load metastatic castration-resistant prostate cancer: a case report and literature review
10.3969/j.issn.1009-8291.2023.03.004
- VernacularTitle:阿比特龙联合泼尼松治疗高危高瘤负荷转移性去势抵抗性前列腺癌1例报道并文献复习
- Author:
Yawei ZHAO
1
;
Lei TANG
1
;
Wang MA
1
;
Zhikun LI
1
;
Yi XIE
2
;
Qianyue LI
1
Author Information
1. Department of Urology, Xinjiang Production and Construction Crops Hospital (Second Affiliated Hospital, School of Medicine, Shihezi University), Urumqi 830002
2. Department of Urology, Peking Union Hospital, Chinese Academy of Medical Sciences, Beijing 100010, China
- Publication Type:Journal Article
- Keywords:
metastatic castration-resistant prostate cancer;
abiraterone;
prostate specific antigen;
treatment
- From:
Journal of Modern Urology
2023;28(3):192-196
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To observe the efficacy of abiraterone (AA) in the treatment of metastatic castration-resistant prostate cancer (mCRPC). 【Methods】 The clinical data of a newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) patient with high risk and high tumor load were analyzed. After operation and endocrine therapy, the disease evolution was observed. Relevant literature was reviewed. 【Results】 After laparoscopic radical prostatectomy, 6-month bicalutamide and androgen deprivation therapy (ADT), the total prostate specific antigen (tPSA) was reduced to the lowest of 0.51 ng/mL, and then increased month by month. After domestic abiraterone (trade name: Qingkeshu) in the 8th month was administered for 4 months, tPSA continued to increase to 12.39 ng/mL. The case was then diagnosed as mCRPC. The treatment was adjusted again in the 11th mouth and the patient received AA (trade name: Zeke) combined with prednisone and ADT, and tPSA decreased to 0.17 ng/mL 2 months later. After 14 months of treatment, tPSA remained at about 0.12 ng/mL. Systemic ECT examination indicated that the range of bone metastases decreased and some areas of nuclide concentration turned shallow without obvious adverse reactions. 【Conclusion】 AA combined with prednisone and ADT can produce rapid decline in PSA and a good response in mCRPC patients. It can also significantly slow the progression of bone metastasis and relieve pain symptoms without obvious adverse reactions. Long-term efficacy needs further observation.
